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Breakout of Vaping-associ-
ated Lung Injuries (VALI)
2019: A Public Health Threat
Sir,
A previously healthy 20 years young man presented in the Emer-
gency Department with worsening shortness of breath for the
last two days. He denied any history of alcohol use or smoking.
He  also  denied  any  history  of  using  additives  while  vaping.
There was no fever, no recent travel history or flu-like illness. He
was a college student with no occupational exposure to any aller-
gens or industrial fumes. He gave the history of using flavoured
e-cigarettes for 2-3 months. Later, he developed intractable
cough and was prescribed oral  azithromycin  by his  primary
physician,  with  no  relief.  On  physical  examination,  he  was
febrile, tachycardic and tachypneic with oxygen saturation of
66% on room air. He had bilateral crepitation on lung ausculta-
tion.
Laboratory work-up showed leukocytosis with neutrophilic shift
(total white cell counts 20 x 109/L with neutrophils 18 x 109/L).
Septic work-up showed raised C-reactive protein of 30 mg/L.
Moreover,  echocardiogram  was  unremarkable.  He  got  intu-
bated due to hypoxemic respiratory failure, increased work of
breathing with respiratory rate of 50 breaths per minute. There
were multiple tiny nodules with no definite infiltrates or consoli-
dation seen on chest X-ray (Figure 1). His blood gas values post-
intubation showed pH of 7.34, PCO2 of 50 mm Hg and PO2 of 75
mm Hg. Rest of the tests’ results were unremarkable. Pipera-
cillin-tazobactam was administered as intravenous antibiotics
and he was shifted to the intensive care unit. Later, he got extu-
bated,  observed  for  two  days  in  ward  and  was  discharged
uneventfully.  CT  chest  was  not  performed  due  to  financial
restraints.  With  the background of  vaping with  flavoured e-
liquid, it was strongly suspected that his vaping exposure posed
a diagnostic challenge. Other possibilities for differential diag-
nosis such as viral or bacterial pulmonary infections, occupa-
tional lung diseases or cardiac conditions were excluded. Such
case made us to be knowledgeable about vaping-related lung
injury (VALI).
Battery operated electronic cigarettes or e-cigarettes are used
to inhale nicotine and additive agents. There has been no large-
scale study identifying such exposure till 2019, when several
journals  and  health  departments  reporting  such  cases  as  a
public health concern. Potentially toxic chemicals such as nico-
tine, carbonyls, benzene, toluene are shown as key ingredients
in vaping.
According  to  the  Center  of  Disease  Control  (CDC),  VALI  is
defined as the use of e-cigarette or vaping in the 90 days before
symptom onset, pulmonary infiltrate (opacities on chest X-ray
or ground glass opacities on computed tomography), absence
of  infection  after  workup and no evidence of  an  alternative
cause (cardiac, rheumatologic, or neoplastic).1-4
Figure 1: Chest X-ray showing bilateral nodularity in lung fields.
Vaping devices in the form of easy-to-carry pens and USB flash
drives have been aggressively marketed. It was first introduced
in the US in 2006. Literature highlighted the short and long term
health  effects  of  vaping  and  its  comparison  with  traditional
cigarettes.  CDC  reported  VALI  with  worsening  symptoms
including shortness of breath, fever, cough, vomiting, diarrhea,
headache, dizziness and chest pain. Range of symptoms and
imaging were correlated with chemical pneumonitis. Patients
required ICU care with mechanical ventilation due to severe
respiratory failure.
As of early September 2019, approximately 450 cases in the
United States were reported with mortality in five cases.5,6 The
largest case number (150-199) was reported from Texas and
Ilinois of United States with 47 deaths.2
The pathogenesis  of  VALI  is  yet  to be discovered;  however,
multiple compounds were identified as potential risk factors
such as diacetyl, nickel, tin, and lead; no specific liquid or device
has  been  identified  as  the  causative  agent.  VALI  has  been
reported with nicotine, tetrahydrocannabinol and cannabidiol
products.  Laboratory  and imaging  findings  are  non-specific.
Bronchoscopy  samples  showed  neutrophilia  and  lipid  laden
macrophages.
The patterns of lung injury reported with VALI include acute
eosinophilic pneumonia, lipoid pneumonia, acute lung injury
and acute respiratory distress syndrome, acute and subacute
hypersensitivity  pneumonitis,  organizing  pneumonia,  acute
eosinophilic  pneumonia,  diffuse  alveolar  hemorrhage,  and
respiratory bronchiolitis-associated pneumonitis.3,6
Emergency physicians should inquire specifically about e-ci-
garette use in any patient presenting with acute lung disease.
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VALI  is  changing  into  an  epidemic  with  under-reported
numbers. In anticipation of rise of respiratory illnesses during
influenza season, the CDC updated its guidance for VALI to help
differentiate these patients from those with seasonal illnesses,
like  influenza.  The  guidance  includes  recommendations  for
physicians to ask patients with respiratory or gastrointestinal
illness, if they have used vaping products or corticosteroids.
Also, a reminder was included that not all patients with VALI
need to be hospitalised; but they can be managed as outpa-
tients if they have normal blood oxygen levels, no respiratory
distress, and reliable access to health care.4-6 Regional data is
non-existent till  now. There is also a dire need to notify the
reported cases to health authorities and spread the awareness
about vaping, which may be considered as a safe option for
smoking  alternatives,  its  marketing  and  testing  of  e-liquid
components.
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